Message from the CEO

We contribute our innovative diagnostic technology to people’s health and medical development.

Our company was founded as Japan’s first antibody manufacturing company in 1969 to continuously take on the innovative diagnostic technology for each life. We take great pride in consistently making straightforward strides with the belief that it is worth accepting the challenge of finding solutions for such diseases that no company has ever confronted.

In 1970s, we initiated the development of diagnostic pharmaceuticals for autoimmune diseases as a leader of the companies of such products in Japan. Furthermore, we launched the distribution of a companion diagnostic (CDx) for the first time in Japan, followed by business evolution that included the development of genetic diagnostic services. In January 2021, our company became a wholly owned subsidiary of JSR Corporation. By further enhancing cooperation with the group companies of JSR Life Sciences, we will provide innovative drug discovery support services in the pharmaceutical and biotechnology industries.

Because future economic conditions and business environment are uncertain, we are willing to transform ourselves for future changes to create the future as intended with backcasting considerations. In particular, the coronavirus disease (COVID-19) that affected the world provided us with the opportunity to reconsider our company’s significance of existence. We will continuously strive to supply our test agents in consideration of our company’s significance of existence for the health and happiness of individuals living every day and a secure society filled with laughter.

We will contribute to people’s health and medical development using our innovative diagnostic technology to meet consistent challenges.

Hiroki Ito